Bleomycin and mitomycin‐C (BLM‐M) in recurrent squamous uterine cervical carcinoma

Charles R. Boice, Ralph S. Freedman, Jay Herson, J. Taylor Wharton, Felix N. Rutledge

Research output: Contribution to journalArticle

Abstract

Bleomycin and mitomycin‐C (BLM‐M) induction therapy was administered to 23 patients with recurrent squamous carcinoma of the uterine cervix. Six patients (26%) responded. Although these results are much lower than originally reported with BLM‐M, there is statistical evidence that patients with disease outside the previous radiation therapy field have improved or more easily determined responses. There was no difference in survival between responders and nonresponders for patients who survived at least six weeks. Therapy was found to be relatively nontoxic with no deaths related to therapy.

Original languageEnglish (US)
Pages (from-to)2242-2245
Number of pages4
JournalCancer
Volume49
Issue number11
DOIs
StatePublished - Jun 1 1982
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Bleomycin and mitomycin‐C (BLM‐M) in recurrent squamous uterine cervical carcinoma'. Together they form a unique fingerprint.

  • Cite this